Navigation Links
Pozen Announces Positive Outcome for PA 325

Chapel Hill, N.C., March 6, 2007-Pozen Inc. (NASDAQ: POZN), today announced top-line results of its "Safer Aspirin" PA 325 proof-of-concept study conducted during the fourth quarter of 2006. PA 325 is a patented formulation of 325mg of aspirin surrounded by a 20mg coating of an immediate release formulation of a proton pump inhibitor.

The PA 325, 28 day study, involved two groups of 40 subjects over the age of 50. Each subject was treated with either once a day commercially available enteric coated aspirin 325mg or PA 325. The primary endpoint was gastrointestinal damage as measured by the Lanza scoring system used in our previous PN studies. The results were highly significant with 10 percent of the PA group having Lanza 3 or 4 gastrointestinal damage, whereas 57.5percent of the enteric coated aspirin group had this level of gastrointestinal damage. Furthermore, no ulcers were seen in the PA group, while 20 percent of subjects in the enteric coated aspirin 325mg group developed a gastric ulcer during the study. This difference was also statistically significant.

Dr. John R. Plachetka, chairman, president and chief executive officer stated, "The data from this first clinical study with PA 325 is very encouraging."

About POZEN

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for the proposed product candidate *Trexima*_ combining sumatriptan, formulated with RT Technology_, and naproxen sodium in a single tablet for the acute treatment of migraine, which is currently under review by the United States Food and Drug
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pozen Announces Positive Outcome for
(Date:11/21/2014)... MELVILLE, N.Y. , Nov. 21, 2014  Cardinal ... the world,s largest health care services companies, and Henry ... largest provider of health care products and services to ... that the companies have entered into a long-term strategic ... and product offerings to office-based medical practices.  This strategic ...
(Date:11/21/2014)... 20, 2014  RedRick Technologies, a provider of ... room environment guidance, has helped the new Penn ... room, which may also serve as a model ... "In line with the tenets ... Radiology,s Imaging 3.0 ™ initiative, the new ...
(Date:11/21/2014)... , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... the Piper Jaffray 26 th Annual Healthcare Conference in ... the Piper Jaffray conference is scheduled for 8:00 am EST (5:00 ... webcast, and the webcast can be accessed via the Investor Relations ... of the webcast will be archived for 30 days on the ...
Breaking Medicine Technology:Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2
(Date:11/22/2014)... AZ (PRWEB) November 22, 2014 Hastings ... with decades of experience announces providing clients with the ... The firm offers clients a flexible, intuitive and easy ... combined with having access to Google + allows clients ... order to make a more informed decision when retaining ...
(Date:11/22/2014)... Petersburg, FL (PRWEB) November 22, 2014 ... Kitchen Innovations are pleased to announce that Ashley ... the Thanksgiving #PayItForward contest. , Ms. Lombardo entered ... from Kitchen Innovations. She wrote of how her friend ... young daughters as a single mom. Despite medical bills ...
(Date:11/22/2014)... 2014 Sandbridge Capital, a private ... the consumer brand sector, acquired a minority stake ... used to help fund BackJoy’s global growth and ... its proprietary apparel and footwear lines. Sandbridge Capital ... of Directors. , BackJoy is a high-growth health ...
(Date:11/22/2014)... Viejo, California (PRWEB) November 22, 2014 Developers ... announced a new plugin entitled FCPX 3D Model bringing the ... “FCPX 3D Model allows users to add obj files to ... Pixel Film Studios. “Blurring the line between professional and armature, ... Model from Pixel Film Studios allows Final Cut Pro X ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Wright & ... AndroGel side-effects lawsuits have been scheduled between October ... Northern District of Illinois. U.S. District Judge Matthew F. ... a Case Management Order (CMO) on November 6, 2014 ... for attorneys to submit documents and other activities in ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
... the University of Copenhagen have collaborated with the company ... of the brain,s complex communication system. The discovery could ... for patients with psychiatric disorders. The results were recently ... to the puzzle of brain functionNew knowledge challenges established ...
... (HealthDay News) -- A calcium test performed with the assistance ... likelihood that certain patients at moderate risk of heart problems ... The test to detect coronary calcium can help physicians ... their cardiovascular risks, the study authors explained. At ...
... Albany, NY (August 18, 2011) AMRI (NASDAQ: ... award from the National Institutes of Health (NIH)/National ... provide chemistry and other drug discovery technologies in ... (MCNP), part of the NIH Blueprint Neurotherapeutics Network. ...
... Reporter , THURSDAY, Aug. 18 (HealthDay News) -- The 2011-12 ... last year,s, but that doesn,t mean it,s OK to skip ... Disease Control and Prevention warn. "All people aged ... Bridges, an associate director for adult immunization at the CDC,s ...
... , THURSDAY, Aug. 18 (HealthDay News) -- Flu vaccination ... recent years but are still below the 2020 national ... the U.S. Centers for Disease Control and Prevention also ... All health care personnel should get an annual ...
... they are more like complex societies, each with a ... Understanding this "social structure" of tumors is critical for ... may be sensitive to different drugs. A common theory ... all cancer cells descend from special self-renewing cancer stem ...
Cached Medicine News:Health News:New piece to the puzzle of brain function 2Health News:Test for Calcium Buildup May Spot Heart Attack, Stroke Risk 2Health News:AMRI receives NIH contract award for development of pre-clinical drug candidates 2Health News:Don't Skip This Year's Flu Shot: CDC 2Health News:Flu Shot Rates Low for Health Workers, Moms-to-Be: CDC 2Health News:Cancer stem cells made, not born 2Health News:Cancer stem cells made, not born 3
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 4.0mm....
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: